Literature DB >> 22670417

Personalised support delivered by support workers for people with severe and persistent mental illness: a systematic review of patient outcomes.

D Siskind1, M Harris, J Pirkis, H Whiteford.   

Abstract

AIMS: Personalised support services assist patients with severe and persistent mental illness (SPMI) to live with functional deficits by providing living skills, emotional support, community access and advocacy. This paper aims to systematically review the evidence for personalised support.
METHODS: Systematic searches of Medline, PsycINFO and Google Scholar (inception to March 2011) identified studies investigating patient outcomes for personalised support services. The quality of the selected studies was assessed. The strength of evidence for the three categories of patient outcomes (illness acuity, personal functioning and patient satisfaction) was graded.
RESULTS: Fifteen studies met inclusion criteria with most rated as having moderate or weak study designs. The selected studies evaluated programs for outpatients with SPMI. There was moderate strength of evidence for reducing illness acuity and improving patient satisfaction with services, and weak strength of evidence for improving personal functioning in studies published to date. Most programs delivered multiple service types, and no clear pattern of service types leading to specific patient outcomes could be discerned.
CONCLUSIONS: Although evidence published to date for personalised support is of variable quality, it suggests that services may be effective. More research on the effects of personalised support subtypes on patient outcomes is required.

Entities:  

Mesh:

Year:  2012        PMID: 22670417     DOI: 10.1017/s2045796011000734

Source DB:  PubMed          Journal:  Epidemiol Psychiatr Sci        ISSN: 2045-7960            Impact factor:   6.892


  7 in total

Review 1.  A domains-based taxonomy of supported accommodation for people with severe and persistent mental illness.

Authors:  Dan Siskind; Meredith Harris; Jane Pirkis; Harvey Whiteford
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2012-10-02       Impact factor: 4.328

2.  Predicting relapse in major depressive disorder using patient-reported outcomes of depressive symptom severity, functioning, and quality of life in the Individual Burden of Illness Index for Depression (IBI-D).

Authors:  Waguih William Ishak; Jared M Greenberg; Robert M Cohen
Journal:  J Affect Disord       Date:  2013-06-19       Impact factor: 4.839

3.  A retrospective quasi-experimental study of a transitional housing program for patients with severe and persistent mental illness.

Authors:  Dan Siskind; Meredith Harris; Steve Kisely; Victor Siskind; James Brogan; Jane Pirkis; David Crompton; Harvey Whiteford
Journal:  Community Ment Health J       Date:  2013-10-23

4.  Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study Report.

Authors:  Emma Morton; Venkat Bhat; Peter Giacobbe; Wendy Lou; Erin E Michalak; Shane McInerney; Trisha Chakrabarty; Benicio N Frey; Roumen V Milev; Daniel J Müller; Sagar V Parikh; Susan Rotzinger; Sidney H Kennedy; Raymond W Lam
Journal:  CNS Drugs       Date:  2021-04-16       Impact factor: 5.749

5.  Linking abuse and recovery through advocacy: an observational study.

Authors:  K Trevillion; S Byford; M Cary; D Rose; S Oram; G Feder; R Agnew-Davies; L M Howard
Journal:  Epidemiol Psychiatr Sci       Date:  2013-04-30       Impact factor: 6.892

6.  Validation of Self-Management Screening (SeMaS), a tool to facilitate personalised counselling and support of patients with chronic diseases.

Authors:  Nathalie Eikelenboom; Ivo Smeele; Marjan Faber; Annelies Jacobs; Frank Verhulst; Joyca Lacroix; Michel Wensing; Jan van Lieshout
Journal:  BMC Fam Pract       Date:  2015-11-11       Impact factor: 2.497

7.  Implementation of personalized self-management support using the self-management screening questionnaire SeMaS; a study protocol for a cluster randomized trial.

Authors:  Nathalie Eikelenboom; Jan van Lieshout; Michel Wensing; Ivo Smeele; Annelies E Jacobs
Journal:  Trials       Date:  2013-10-17       Impact factor: 2.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.